Robin Hood Ventures
Robin Hood Ventures is a group of angel investors, focused on early-stage, high-growth companies in the Greater Philadelphia region. We help entrepreneurs build great companies, providing capital, mentoring, expertise and connections to help companies reach their potential. Robin Hood generally invests $250k to $500k, and collaborates with angels, institutions and VCs in our network. We invest as a single entity in businesses we know and understand, in a way that gets deals done. Since 1999, we have invested in over 45 companies in industries including software, medical devices, biotech, internet and financial technology.
BiologicsMD
Corporate Round in 2024
BiologicsMD, Inc. is a therapeutic development company based in Fayetteville, Arkansas, established in 2010. The company specializes in creating targeted therapies for hair loss and severe bone disorders. Its product pipeline includes BMD-1141, a hair cycle stimulator aimed at restoring normal hair growth and preventing hair loss by stimulating the hair cycle, and BMD-1231, a bone graft substitute designed for spinal fusion procedures. BiologicsMD focuses on developing recombinant fusion proteins that deliver potent stimulatory effects directly to specific receptors at the site of disease, allowing for sustained therapeutic exposure with either a single dose or infrequent dosing regimens. The company is also exploring various formulation and delivery methods for parenteral, local, and topical administration of its therapies.
BiologicsMD
Venture Round in 2022
BiologicsMD, Inc. is a therapeutic development company based in Fayetteville, Arkansas, established in 2010. The company specializes in creating targeted therapies for hair loss and severe bone disorders. Its product pipeline includes BMD-1141, a hair cycle stimulator aimed at restoring normal hair growth and preventing hair loss by stimulating the hair cycle, and BMD-1231, a bone graft substitute designed for spinal fusion procedures. BiologicsMD focuses on developing recombinant fusion proteins that deliver potent stimulatory effects directly to specific receptors at the site of disease, allowing for sustained therapeutic exposure with either a single dose or infrequent dosing regimens. The company is also exploring various formulation and delivery methods for parenteral, local, and topical administration of its therapies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.